BSE Sensex 30 Stocks Regulatory Filings — October 20, 2026

19-10-2026

UltraTech Cement Limited's Nomination, Remuneration and Compensation Committee granted 3,536 stock options under the Employee Stock Option and Performance Stock Unit Scheme, 2022, on 19 October 2026. The grant comprises 3,220 stock options and 316 Performance Stock Units (PSUs), issued to eligible employees under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. This is a routine employee compensation disclosure with no reported change in financial performance.

• · Stock options must be exercised within 5 years from the date of vesting
• · Exercise price for options is based on the Market Price as of 16 October 2026, per SEBI SBEB and Sweat Equity Regulations 2021
• · Grant is disclosed to BSE, NSE, Luxembourg Stock Exchange and Singapore Exchange, indicating listings across these venues

20-10-2026

NTPC Limited issued a Regulation 30 clarification on 20 October 2026 stating that a news article published by AD HOC News, headlined 'NTPC Posts 7.43 Percent Profit Growth; Buyback Sets Date for NTPC Stock', is factually incorrect and misleading. The Company says the article's statements do not correspond with any disclosure it has made to the stock exchanges, and advises investors to rely only on official exchange filings and its website. The Company is taking up the matter with the publisher for corrective action.

• · The filing references Scrip Code 532555, Symbol NTPC, and ISIN INE733E01010
• · The Company has not confirmed any buyback announcement; the buyback reference appears only in the disputed news headline
• · The Company is pursuing corrective action with the publisher of the article

20-10-2026

Sun Pharmaceutical Industries intimated the NSE and BSE under Regulation 30 of the post-announcement of a press release that UNLOXCYT (cosibelimab-ipdl) was elevated to an NCCN Category 2A recommended option for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation. The designation follows a Category 2A designation in metastatic CSCC assigned in 2025. The pivotal study reported a 55% objective response rate (26% complete response) at a median follow-up of 24.1 months, with fewer than 1% of patients experiencing high-grade immune-mediated adverse reactions.

• · UNLOXCYT was approved by the FDA in 2024 and is the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC
• · Recommended dosage is 1,200 mg IV over 60 minutes every 3 weeks
• · No grade 4 or 5 immune-mediated adverse reactions were reported in the pivotal study
• · Most common adverse reactions (≥10%) include fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection
• · Median duration of response had not been reached (range 8.3 to 31.3+ months)

20-10-2026

Titan Company Limited has notified the stock exchanges that its Board of Directors will meet on Thursday, 5th November 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026. The results will be published immediately after the Board meeting. The company's trading window for designated persons and their immediate relatives remains closed from 23rd September 2026 and will reopen 48 hours after the conclusion of the Board meeting.

• · Board meeting date: Thursday, 5th November 2026
• · Trading window closed since 23rd September 2026 (per letter SEC 75 / 2026-27 dated 22nd September 2026)
• · Trading window to reopen 48 hours after conclusion of the Board meeting
• · Filing made under Regulation 29(1)(a) of SEBI LODR Regulations, 2015